TABLE 5.
Susceptibility to additional low- and high-molecular-weight drugs of the site-directed constructed (chromosome-based) AcrB I38F I671T double mutant strain compared to the ΔAcrB mutant and wild-type AcrB-overexpressing strain 3-AG100
| Strain | MIC (μg/ml)a |
|||||||
|---|---|---|---|---|---|---|---|---|
| TEDb | MIN | MXF | CIP | RIX | OLMb | TYL | JOS | |
| ΔAcrB mutant | 1 | 0.125 | 0.06 | 0.06 | 4 | 4 | 16 | 4 |
| 3-AG100 | >512 | 4 | 4 | 2 | 64 | 512 | 1,024 | 1,024 |
| I38F I671T mutant | 4 | 0.25 | 0.25 | 0.13 | 16 | >512 | 1,024 | 1,024 |
a
TED, tedizolid; MIN, minocycline; MXF, moxifloxacin; CIP, ciprofloxacin; RIX, rifaximin. Macrolides: OLM, oleandomycin; TYL, tylosin; JOS, josamycin. MIC changes of ≥4-fold detected from the double mutant compared to the parental wild-type AcrB-overexpressing strain 3-AG100 are in boldface.
b
With TED and OLM, the solubility of the drugs in broth was limited to the MICs detected with strain 3-AG100 and the I38F I671T double mutant, respectively.